Article Listing - Kimia Farma ready to sell stake in RAF
BOOTS TO COPROMOTE W-L'S LOPID
10 February 1992
Boots Co has announced that its wholly-owned US subsidiary, Boots Pharmaceuticals Inc, has commenced the copromotion of Warner-Lambert subsidiary Parke-Davis'...
NEW YORK MEETINGS
10 February 1992
Two industry-related meetings are due to be held soon at the Loews Summit Hotel, New York: Cost Containment and Quality...
NEW FORMULATION OF JANSSEN'S NIZORAL
10 February 1992
Janssen Pharmaceutical has launched a new unperfumed, less viscous formulation of its Nizoral (ketoconazole) shampoo in the UK. Nizoral, Janssen...
FEMALE CONDOM RECOMMENDED FOR USA
10 February 1992
The Obstetrics and Gynec-ology Devices Advisory Commit-tee of the US Food and Drug Administration has recommended approval of Chartex Inter-national's...
SPAIN LOOKING TO GENERICS
10 February 1992
The full incorporation of Spain into the European Community, which takes effect on October 7, means that the country will...
EC "BLOW" TO NEW OTC PRODUCTS
10 February 1992
As it now stands, the Commission of the European Communities' proposed directive on advertising of over-the counter products in the...
US FDA TAKING LONGER TO APPROVE NEW DRUGS
10 February 1992
The US Food and Drug Administra-tion is taking longer to review new drugs, and in 1991 required an average of...
INDUSTRY RESPONSE TO JAPAN DRUG PRICE MOVES
10 February 1992
The Koseisho, Japan's Ministry of Health and Welfare, is in the process of clarifying how it intends to implement the...
STOCK MARKET COMMENTARY: EUROPE
10 February 1992
EUROPE: saw most stock markets down by the end of the reporting period, with FRANKFURT doing marg-inally better. Among the...
GOOD YEAR FOR SANOFI IN 1991
10 February 1992
In 1991 sales at the French health and beauty concern, Elf Sanofi, increased 5.8% to 19.6 billion French francs ($3.6...
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
